Evangelos Terpos to Denosumab
This is a "connection" page, showing publications Evangelos Terpos has written about Denosumab.
Connection Strength
3.538
-
Controversies in the use of new bone-modifying therapies in multiple myeloma. Br J Haematol. 2021 Jun; 193(6):1034-1043.
Score: 0.859
-
Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis. Hematology. 2019 Dec; 24(1):318-324.
Score: 0.801
-
Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. Blood Adv. 2018 11 13; 2(21):2837-2847.
Score: 0.745
-
Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis. Endocrine. 2018 11; 62(2):487-489.
Score: 0.731
-
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. J Med Econ. 2018 May; 21(5):525-536.
Score: 0.178
-
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018 03; 19(3):370-381.
Score: 0.177
-
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treat Rev. 2019 Jun; 76:57-67.
Score: 0.048